{
  "url": "https://openlegislation.uk/draft-infected-blood-compensation-scheme-regulations-2025/schedule-2/paragraph-3",
  "json_url": "https://openlegislation.uk/draft-infected-blood-compensation-scheme-regulations-2025/schedule-2/paragraph-3.json",
  "legislation": "ukdsi/2025/9780348268843",
  "legislation_title": "The Infected Blood Compensation Scheme Regulations 2025",
  "legislation_url": "https://openlegislation.uk/draft-infected-blood-compensation-scheme-regulations-2025",
  "path": "schedule/2/paragraph/3",
  "kind": "paragraph",
  "number": "3",
  "heading": "Neurological conditions resulting in long-term severe physical disability",
  "text": "(1) A person (“P”) is to be treated as having a neurological condition resulting in long-term severe physical disability if—\n(a) P has—\n(i) HIV and has been diagnosed with any of the conditions listed in sub-paragraph (2);\n(ii) a Hepatitis B infection of severity level 2, 3 or 4 and has been diagnosed with any of the conditions listed in sub-paragraph (3);\n(iii) a Hepatitis C infection of severity level 2, 3 or 4 and has been diagnosed with any of the conditions listed in sub-paragraph (4), and\n(b) P has been assessed as needing at least level 2 care as a result of the diagnosed condition.\n(2) The conditions referred to in sub-paragraph (1)(a)(i) are—\n(a) any of the following conditions, if the condition is secondary to advanced HIV disease and neoplasia secondary to that disease—\n(i) cerebral toxoplasmosis;\n(ii) central nervous system tuberculosis;\n(iii) cytomegalovirus encephalitis;\n(iv) varicella zoster virus encephalitis;\n(v) herpes simplex virus encephalitis;\n(vi) Epstein Barr virus encephalitis;\n(vii) progressive multifocal leucoencephalopathy;\n(viii) cryptococcal meningitis;\n(ix) primary central nervous system lymphoma;\n(x) thromboembolic disease secondary to bacterial or fungal endocarditis;\n(b) any of the following conditions, secondary to, or associated with, HIV infection—\n(i) HIV vacuolar myelopathy;\n(ii) transverse myelitis;\n(iii) thrombotic thrombocytopenic purpura;\n(iv) cerebrovascular ischaemic or haemorrhagic stroke;\n(v) coagulopathies: Antiphospholipid syndrome;\n(vi) chronic inflammatory demyelinating polyneuropathy;\n(vii) cytomegalovirus polyradiculopathy;\n(viii) HIV myopathy.\n(3) The conditions referred to in sub-paragraph (1)(a)(ii) are—\n(a) peripheral neuropathy caused by mixed cryoglobulinaemic vasculitis that results in mobility disability;\n(b) peripheral neuropathy occurring in the context of Hepatitis B-associated polyarteritis nodosa that results in mobility disability.\n(4) The conditions referred to in sub-paragraph (1)(a)(iii) are—\n(a) cryoglobulinaemic vasculitis induced neurological disease that results in mobility disability;\n(b) peripheral neuropathy caused by mixed cryoglobulinaemic vasculitis that results in mobility disability.",
  "extent": null,
  "status": null,
  "version": "current",
  "annotations": [],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/ukdsi/2025/9780348268843/schedule/2/paragraph/3",
    "retrieved_at": "2026-10-30T14:39:35.762697+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}